BridgeBio Oncology Therapeutics (BBOT) Operating Leases (2025 - 2026)

BridgeBio Oncology Therapeutics (BBOT) posted Operating Leases of $2.1 million for Q1 2026, down 6.15% sequentially from $2.2 million in Q4 2025.

BridgeBio Oncology Therapeutics (BBOT) Operating Leases (2025 - 2026) Analysis & Trends

BridgeBio Oncology Therapeutics has reported Operating Leases for 2 years, with the latest figure at $2.1 million in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (changed N/A YoY) and the FY2025 annual result came in at $2.2 million, changed N/A from the prior year.
Operating Leases retreated to $2.1 million in Q1 2026 per BBOT's latest filing, from $2.2 million in the prior quarter.
Over five years, Operating Leases peaked at $2.4 million in Q3 2025 and troughed at $2.1 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	BridgeBio Oncology Therapeutics	726.38 Mn	500.67 Mn	-

Download Data